Aurora Cannabis 将来の成長
Future 基準チェック /16
Aurora Cannabisは、96.8%と5.5%でそれぞれ年率96.8%で利益と収益が成長すると予測される一方、EPSはgrowで84.8%年率。
主要情報
96.8%
収益成長率
84.80%
EPS成長率
| Pharmaceuticals 収益成長 | 14.7% |
| 収益成長率 | 5.5% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 29 Jun 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Jul 07
ACB: Medical Focus And Rescheduling Tailwinds Will Drive Future Upside Potential
Aurora Cannabis’ updated analyst price target has moved from CA$10.00 to CA$8.00 as analysts factor in lower modeled profit margins, a higher discount rate, and more conservative revenue growth assumptions, despite viewing recent partial cannabis rescheduling efforts as extremely favorable for the sector. What is in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining a plan to exit lower margin Canadian consumer and plant propagation businesses and concentrate resources on global medical cannabis, with a focus on markets such as Germany and Poland.
ナラティブ更新 • Jun 23
ACB: Favorable Rescheduling Outlook Will Support Shift To Global Medical Focus
Analysts have revised their fair value estimate for Aurora Cannabis from CA$7.93 to CA$6.14, citing updated expectations for revenue growth, profit margins, and a higher future P/E multiple following recent research that views partial cannabis rescheduling as extremely favorable for the sector. What’s in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining plans to exit lower margin Canadian consumer and plant propagation businesses and to concentrate resources on global medical cannabis, with a focus on what the company views as higher return opportunities.
ナラティブ更新 • Jun 05
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.ナラティブ更新 • May 09
ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.ナラティブ更新 • Apr 20
ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.ナラティブ更新 • Apr 05
ACB: Revised P E Assumptions And Policy Signals Will Guide Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1 as analysts factor in updated views on revenue trends, margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent research updates point to a more cautious tone around Aurora Cannabis, as analysts reassess what they are willing to pay for the stock in light of current revenue and margin expectations.ナラティブ更新 • Mar 22
ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.ナラティブ更新 • Mar 07
ACB: Policy Shifts And Margin Execution Will Shape Fairly Balanced Outlook
Narrative update overview The latest analyst update trims the Aurora Cannabis price target by CA$1. This reflects a shift to lower expected profit margins and a higher assumed future P/E multiple, while still leaning on prior bullish initiation as support for the longer-term story.ナラティブ更新 • Feb 21
ACB: Policy Shift And Execution Uncertainty Will Shape Balanced Risk Profile
Aurora Cannabis: Narrative Update Analysts reduced their 12-month price target for Aurora Cannabis by CA$1. This reflects updated expectations that now assume slightly softer revenue growth, somewhat higher profit margins, and a lower future P/E multiple.ナラティブ更新 • Feb 06
ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead
Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.分析記事 • Nov 07
Aurora Cannabis Inc. (TSE:ACB) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...分析記事 • Oct 03
Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Aug 29
Aurora Cannabis Inc. (TSE:ACB) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Aurora Cannabis Inc. ( TSE:ACB ) shares have had a really impressive month, gaining 27% after a shaky period...ナラティブ更新 • Aug 07
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92. What's in the News Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).分析記事 • Jul 12
Aurora Cannabis Inc. (TSE:ACB) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...分析記事 • Jun 26
Aurora Cannabis' (TSE:ACB) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Aurora Cannabis Inc. ( TSE:ACB ) recently. We did some...分析記事 • May 23
After Leaping 29% Aurora Cannabis Inc. (TSE:ACB) Shares Are Not Flying Under The Radar
Those holding Aurora Cannabis Inc. ( TSE:ACB ) shares would be relieved that the share price has rebounded 29% in the...
新しいナラティブ • Apr 26
EU GMP And TGA Expertise Will Expand Global Cannabis Reach
Strategic international expansion and regulatory changes in key markets could significantly boost future revenues and medical cannabis margins.分析記事 • Feb 04
Investors Give Aurora Cannabis Inc. (TSE:ACB) Shares A 26% Hiding
Unfortunately for some shareholders, the Aurora Cannabis Inc. ( TSE:ACB ) share price has dived 26% in the last thirty...分析記事 • Nov 22
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shareholders that were waiting for something to happen have been dealt a blow with a...分析記事 • Aug 02
It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Key Insights Aurora Cannabis to hold its Annual General Meeting on 9th of August Salary of CA$773.6k is part of CEO...分析記事 • Jun 27
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...分析記事 • Feb 15
Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem
We didn't see Aurora Cannabis Inc.'s ( TSE:ACB ) stock surge when it reported robust earnings recently. We decided to...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2029 | 365 | N/A | N/A | N/A | 1 |
| 3/31/2028 | 319 | -3 | 9 | 21 | 5 |
| 3/31/2027 | 293 | -26 | -6 | 0 | 6 |
| 3/31/2026 | 321 | -59 | -36 | -14 | N/A |
| 12/31/2025 | 373 | -84 | -31 | -10 | N/A |
| 9/30/2025 | 367 | -57 | -18 | 2 | N/A |
| 6/30/2025 | 358 | -3 | -1 | 18 | N/A |
| 3/31/2025 | 289 | 27 | 1 | 16 | N/A |
| 12/31/2024 | 320 | 15 | -29 | -9 | N/A |
| 9/30/2024 | 296 | -29 | -61 | -43 | N/A |
| 6/30/2024 | 278 | -30 | -67 | -49 | N/A |
| 3/31/2024 | 270 | -53 | -85 | -69 | N/A |
| 12/31/2023 | 266 | -108 | -91 | -71 | N/A |
| 9/30/2023 | 262 | -153 | -145 | -127 | N/A |
| 6/30/2023 | 248 | -195 | -141 | -127 | N/A |
| 3/31/2023 | 224 | -793 | -163 | -142 | N/A |
| 12/31/2022 | 212 | -1,748 | -181 | -157 | N/A |
| 9/30/2022 | 210 | -1,757 | -152 | -118 | N/A |
| 6/30/2022 | 221 | -1,718 | -142 | -110 | N/A |
| 3/31/2022 | 226 | -1,233 | -98 | -64 | N/A |
| 12/31/2021 | 231 | -381 | -122 | -82 | N/A |
| 9/30/2021 | 238 | -607 | -165 | -124 | N/A |
| 6/30/2021 | 245 | -692 | -264 | -211 | N/A |
| 3/31/2021 | 257 | -2,387 | -357 | -284 | N/A |
| 12/31/2020 | 275 | -2,359 | -430 | -285 | N/A |
| 9/30/2020 | 263 | -3,342 | -614 | -357 | N/A |
| 6/30/2020 | 269 | -3,231 | -691 | -342 | N/A |
| 3/31/2020 | 299 | -1,405 | -778 | -293 | N/A |
| 12/31/2019 | 291 | -1,430 | N/A | -289 | N/A |
| 9/30/2019 | 290 | -385 | N/A | -218 | N/A |
| 6/30/2019 | 246 | -294 | N/A | -192 | N/A |
| 3/31/2019 | 168 | -211 | N/A | -233 | N/A |
| 12/31/2018 | 119 | -72 | N/A | -206 | N/A |
| 9/30/2018 | 77 | 174 | N/A | -146 | N/A |
| 6/30/2018 | 55 | 72 | N/A | -82 | N/A |
| 3/31/2018 | 42 | -13 | N/A | -35 | N/A |
| 12/31/2017 | 31 | 7 | N/A | -16 | N/A |
| 9/30/2017 | 23 | -4 | N/A | -15 | N/A |
| 6/30/2017 | 18 | -13 | N/A | -13 | N/A |
| 3/31/2017 | 13 | -16 | N/A | -17 | N/A |
| 12/31/2016 | 8 | -13 | N/A | -11 | N/A |
| 9/30/2016 | 5 | -10 | N/A | -9 | N/A |
| 6/30/2016 | 1 | -6 | N/A | -7 | N/A |
| 3/31/2016 | 0 | 0 | N/A | -5 | N/A |
| 12/31/2015 | N/A | -3 | N/A | -3 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ACB今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ACB今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: ACB今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: ACBの収益 ( 5.5% ) Canadian市場 ( 4.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: ACBの収益 ( 5.5% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ACBの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/13 18:22 |
| 終値 | 2026/07/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Aurora Cannabis Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Etienne Ricard | BMO Capital Markets Equity Research |
| Heather Balsky | BofA Global Research |